CEROW
CERo Therapeutics Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
−26.92%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -79.5%
- EBIT
- -16.9%
- EPS
- -47.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -20.7%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026